204 related articles for article (PubMed ID: 17201405)
1. Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors.
Goodman KB; Cui H; Dowdell SE; Gaitanopoulos DE; Ivy RL; Sehon CA; Stavenger RA; Wang GZ; Viet AQ; Xu W; Ye G; Semus SF; Evans C; Fries HE; Jolivette LJ; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Jung DK; Wright LL; Smith GK; Behm DJ; Bentley R; Doe CP; Hu E; Lee D
J Med Chem; 2007 Jan; 50(1):6-9. PubMed ID: 17201405
[TBL] [Abstract][Full Text] [Related]
2. Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity.
Stavenger RA; Cui H; Dowdell SE; Franz RG; Gaitanopoulos DE; Goodman KB; Hilfiker MA; Ivy RL; Leber JD; Marino JP; Oh HJ; Viet AQ; Xu W; Ye G; Zhang D; Zhao Y; Jolivette LJ; Head MS; Semus SF; Elkins PA; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Jung DK; Wright LL; Smith GK; Behm DJ; Doe CP; Bentley R; Chen ZX; Hu E; Lee D
J Med Chem; 2007 Jan; 50(1):2-5. PubMed ID: 17201404
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of Rho kinase inhibitors (II).
Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
[TBL] [Abstract][Full Text] [Related]
4. Rho-kinase inhibition suppresses bladder hyperactivity in spontaneously hypertensive rats.
Rajasekaran M; Wilkes N; Kuntz S; E Albo M
Neurourol Urodyn; 2005; 24(3):295-300. PubMed ID: 15791631
[TBL] [Abstract][Full Text] [Related]
5. Rho-kinase inhibitor may exert a role in preventing cardiac hypertrophy, independent of antihypertensive effects.
Pan M; Jing HM; Zhu JH; Liu ZH; Jiang WP; Yang XJ
Med Hypotheses; 2007; 68(1):234. PubMed ID: 16919397
[No Abstract] [Full Text] [Related]
6. Chronic fluvastatin treatment alters vascular contraction by inhibiting the Rho/Rho-kinase pathway.
Kansui Y; Fujii K; Goto K; Oniki H; Iida M
Clin Exp Pharmacol Physiol; 2006 Aug; 33(8):673-8. PubMed ID: 16895538
[TBL] [Abstract][Full Text] [Related]
7. A Rho-kinase inhibitor, Y-27632, reduces cholinergic contraction but not neurotransmitter release.
Fernandes L; D'Aprile A; Self G; McGuire M; Sew T; Henry P; Goldie R
Eur J Pharmacol; 2006 Nov; 550(1-3):155-61. PubMed ID: 17010334
[TBL] [Abstract][Full Text] [Related]
8. Rho-kinase as a potential therapeutic target for the treatment of pulmonary hypertension.
Xing XQ; Gan Y; Wu SJ; Chen P; Zhou R; Xiang XD
Drug News Perspect; 2006 Nov; 19(9):517-22. PubMed ID: 17220956
[TBL] [Abstract][Full Text] [Related]
9. Rho kinase inhibitors as potential therapeutic agents for cardiovascular diseases.
Hu E; Lee D
Curr Opin Investig Drugs; 2003 Sep; 4(9):1065-75. PubMed ID: 14582450
[TBL] [Abstract][Full Text] [Related]
10. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.
Sehon CA; Wang GZ; Viet AQ; Goodman KB; Dowdell SE; Elkins PA; Semus SF; Evans C; Jolivette LJ; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Wright LL; Smith GK; Behm DJ; Bentley R; Doe CP; Hu E; Lee D
J Med Chem; 2008 Nov; 51(21):6631-4. PubMed ID: 18842034
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for induced-fit binding of Rho-kinase to the inhibitor Y-27632.
Yamaguchi H; Miwa Y; Kasa M; Kitano K; Amano M; Kaibuchi K; Hakoshima T
J Biochem; 2006 Sep; 140(3):305-11. PubMed ID: 16891330
[TBL] [Abstract][Full Text] [Related]
12. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease.
Budzyn K; Marley PD; Sobey CG
Trends Pharmacol Sci; 2006 Feb; 27(2):97-104. PubMed ID: 16376997
[TBL] [Abstract][Full Text] [Related]
13. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
[TBL] [Abstract][Full Text] [Related]
14. Rho kinase as a novel molecular therapeutic target for hypertensive internal anal sphincter.
Rattan S; De Godoy MA; Patel CA
Gastroenterology; 2006 Jul; 131(1):108-16. PubMed ID: 16831595
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of a novel selective Rho kinase inhibitor, 2-(1H-indazole-5-yl)amino-4-methoxy-6-piperazino triazine (DW1865).
Oh KS; Oh BK; Park CH; Seo HW; Kang NS; Lee JH; Lee JS; Ho Lee B
Eur J Pharmacol; 2013 Feb; 702(1-3):218-26. PubMed ID: 23376156
[TBL] [Abstract][Full Text] [Related]
16. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.
Sutherlin DP; Sampath D; Berry M; Castanedo G; Chang Z; Chuckowree I; Dotson J; Folkes A; Friedman L; Goldsmith R; Heffron T; Lee L; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Olivero A; Pang J; Prior WW; Salphati L; Sideris S; Tian Q; Tsui V; Wan NC; Wang S; Wiesmann C; Wong S; Zhu BY
J Med Chem; 2010 Feb; 53(3):1086-97. PubMed ID: 20050669
[TBL] [Abstract][Full Text] [Related]
17. Heat shock augments myosin phosphatase target-subunit phosphorylation.
Kim JI; Jeon SB; Baek I; Seok YM; Shin HM; Kim IK
Biochem Biophys Res Commun; 2007 May; 356(3):718-22. PubMed ID: 17382904
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of 4-(1-aminoalkyl)-N-(4-pyridyl)cyclohexanecarboxamides as Rho kinase inhibitors and neurite outgrowth promoters.
Gingras K; Avedissian H; Thouin E; Boulanger V; Essagian C; McKerracher L; Lubell WD
Bioorg Med Chem Lett; 2004 Oct; 14(19):4931-4. PubMed ID: 15341954
[TBL] [Abstract][Full Text] [Related]
19. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4.
Powers JP; Li S; Jaen JC; Liu J; Walker NP; Wang Z; Wesche H
Bioorg Med Chem Lett; 2006 Jun; 16(11):2842-5. PubMed ID: 16563752
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of certain new 2,4,5(6) trisubstituted-1,2,4-triazolo[1,5-alpha]pyrimidines as potential antihypertensive agents.
Bayomi SM; Abdelal AM; el-Ashry SM; Ghoneim OA
Boll Chim Farm; 1999 May; 138(5):227-32. PubMed ID: 10450124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
